gabapentin, Neurontin, Gralise, Horizant, Fanatrex FusePag (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
The recommended dose for postherpetic neuralgia is 1800 mg daily in 3 divided doses (Neurontin) or 1800 mg once daily (Gralise). Gralise is not interchangeable with other gabapentin products. Seizures are treated with 900-1800 mg/daily in 3 divided doses (Neurontin). Withdrawal of treatment should occur slowly over a week.
DRUG INTERACTIONS: Antacids reduce the concentration of gabapentin in blood. Therefore, gabapentin should be administered 2 hours or more after taking antacids. Morphine significantly increases blood concentrations of gabapentin and may increase central nervous system-related adverse events associated with gabapentin.
PREGNANCY AND BREASTFEEDING SAFETY: Safety in pregnancy has not been established.
Gabapentin is secreted in human breast milk. Nursing mothers should only use gabapentin if the benefits outweigh the unknown risk to the fetus.
STORAGE: Tablets and capsules should be stored between 15 C to 30 C (59 F to 86 F). Gabapentin solution should be refrigerated between 2 C to 8 C (36 F to 46 F).
DOSING: Gabapentin may be taken with or without food.
DRUG CLASS AND MECHANISM: Gabapentin is an anti-sizure (anti-convulsant) drug that is used for preventing seizures and for treating post-herpetic neuralgia, the pain that follows an episode of shingles. The mechanism of action of gabapentin is not known. Gabapentin structurally resembles the neurotransmitter gamma aminobutyric acid (GABA). (Neurotransmitters are drugs that nerves use to communicate with one another.) It is possible that this similarity is related to gabapentin's mechanism of action. In animal models used for testing the anticonvulsant and analgesic (anti-pain) activities of drugs, gabapentin prevents seizures and reduces pain-related responses. The FDA approved gabapentin in December 1993.
Medically reviewed by Eni Williams, PharmD
REFERENCE: FDA Prescribing Information
Medically Reviewed by a Doctor on 3/30/2016
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index